title: [Role of TGF-beta, IL-10 and IL-17 in allergic rhinitis patients with specific immunotherapy].
abstract: To detect the level of TGF-beta, IL-10 and IL-17 in the allergic rhinitis(AR) patients pre- and post-specific immunotherapy (SIT).
  
  
  
  The level of TGF-beta, IL-10 and IL-17 in serum of 48 AR patients were detected by enzyme-linked immunosorbent assay before SIT. and the nasal symptom score (NSS) was evaluated in the first and second year after SIT. At the same time. 35 healthy persons were made as normal.
  
  
  
  (1) The level of TGF-beta and IL-10 in serum of AR patients were lower than that of normal group (P < 0.05). The level of TGF-beta and IL-10 in AR patients taken SIT for two years was lower than that of patients with one year SIT (P < 0.05), but it was higher than that of patients pre-immunotherapy (P < 0.05). However, The level of TGF-beta and IL-10 in the group that taken SIT for two years was still lower than that of normal group (P < 0.05). (2) The level of IL-17 in serum of AR patients pre- immunotherapy was higher than that of normal group (P < 0.05). The level of IL-17 continuously declined after taking SIT, However it was higher than that of normal group two years later (P < 0.05). (3) In AR patients pre-immunotherapy and post- immunotherapy for 2 years, the level of IL-10 and TGF-beta showed negative correlation with NSS respectively, the level of IL-17 was positive related to NSS respectively (P < 0.05). But the level of IL-10, TGF-beta and IL-17 showed no correlation with NSS respectively (P > 0.05) when SIT was taken for one year.
  
  
  
  IL-10 and TGF-beta were fluctuated in AR patients taking SIT, which raised first and then dropped. but the level of IL-10 and TGF-beta was higher than that of pre- immunotherapy. However, the level of IL-17 continuously declined in the whole process. It showed that the level change of IL-10, TGF-beta and IL-17 correlate with patients' symptom only two years after SIT,so the level change of IL-10, TGF-beta and IL-17 can be used as an index for evaluating the treatment effectiveness of SIT at that time.
authors.affiliation: Department of Otolaryngology, Shantou Central Hospital, Shantou, 515031, China.
authors.forename: Hangui
authors.initials: HG
authors.lastname: Lu
authors.forename: Qianhui
authors.initials: QH
authors.lastname: Qiu
authors.forename: Chuan
authors.initials: C
authors.lastname: Lu
authors.forename: Shaohua
authors.initials: SH
authors.lastname: Chen
authors.forename: Hong
authors.initials: H
authors.lastname: Han
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002648:Child; D005260:Female; D006801:Humans; D007167:Immunotherapy; D016753:Interleukin-10 / Q000097:blood*; D020381:Interleukin-17 / Q000097:blood*; D008297:Male; D012221:Rhinitis, Allergic, Perennial / Q000097:blood* / Q000628:therapy*; D016212:Transforming Growth Factor beta / Q000097:blood*; D055815:Young Adult
chemical_list: D020381:Interleukin-17; D016212:Transforming Growth Factor beta; D016753:Interleukin-10